An individualized risk calculator for research in prodromal psychosis

American Journal of Psychiatry

Volumn 173, Issue 10, 2016, Pages 980-988

  Cannon, Tyrone D ^a   Yu, Changhong ^a   Addington, Jean ^a   Bearden, Carrie E ^a   Cadenhead, Kristin S ^a   Cornblatt, Barbara A ^a   Heinssen, Robert ^a   Jeffries, Clark D ^a   Mathalon, Daniel H ^a   McGlashan, Thomas H ^a   Perkins, Diana O ^a   Seidman, Larry J ^a   Tsuang, Ming T ^a   Walker, Elaine F ^a   Woods, Scott W ^a   Kattan, Michael W ^a  

^a EMORY UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADOLESCENT; AGE; ARTICLE; COHORT ANALYSIS; CONTROLLED STUDY; DISEASE SEVERITY; FAMILY HISTORY; FEMALE; FOLLOW UP; HIGH RISK PATIENT; HUMAN; LEARNING; LIFE EVENT; LIFE STRESS; MAJOR CLINICAL STUDY; MALE; MEMORY; PREDICTOR VARIABLE; PRIORITY JOURNAL; PRODROMAL SYMPTOM; PSYCHOSIS; RISK ASSESSMENT; RISK FACTOR; SLOWNESS; SOCIAL INTERACTION; SUSPICIOUSNESS; CLINICAL TRIAL; EARLY DIAGNOSIS; LONGITUDINAL STUDY; MULTICENTER STUDY; PREDICTIVE VALUE; PSYCHOLOGICAL RATING SCALE; PSYCHOTIC DISORDERS;

ADOLESCENT; EARLY DIAGNOSIS; HUMANS; LONGITUDINAL STUDIES; PREDICTIVE VALUE OF TESTS; PRODROMAL SYMPTOMS; PSYCHIATRIC STATUS RATING SCALES; PSYCHOTIC DISORDERS; RISK FACTORS;

EID: 84991363477     PISSN: 0002953X     EISSN: 15357228     Source Type: Journal    
DOI: 10.1176/appi.ajp.2016.15070890     Document Type: Article

References (42)

1. Insel TR: The arrival of preemptive psychiatry. Early Interv Psychiatry 2007; 1:5-6
2. Fusar-Poli P, Bonoldi I, Yung AR, et al: Predicting psychosis: metaanalysis of transition outcomes in individuals at high clinical risk. Arch Gen Psychiatry 2012; 69:220-229
3. Cannon TD, Cadenhead K, Cornblatt B, et al: Prediction of psychosis in youth at high clinical risk: a multisite longitudinal study in North America. Arch Gen Psychiatry 2008; 65:28-37
4. Fusar-Poli P, Borgwardt S, Bechdolf A, et al: The psychosis high-risk state: a comprehensive state-of-the-art review. JAMA Psychiatry 2013; 70:107-120
5. KattanMW,YuC, Stephenson AJ, et al: Clinicians versusnomogram: predicting future technetium-99m bone scan positivity in patients with rising prostate-specific antigen after radical prostatectomy for prostate cancer. Urology 2013; 81:956-961
6. Lee TH, Marcantonio ER, Mangione CM, et al: Derivation and prospective validation of a simple index for prediction of cardiac risk of major noncardiac surgery. Circulation 1999; 100:1043-1049
7. Pfeiffer RM, Park Y, Kreimer AR, et al: Risk prediction for breast, endometrial, and ovarian cancer in white women aged 50 y or older: derivation and validation from population-based cohort studies. PLoS Med 2013; 10:e1001492
8. Ross PL, Gerigk C, Gonen M, et al: Comparisons of nomograms and urologists' predictions in prostate cancer. Semin Urol Oncol 2002; 20:82-88
9. SpechtMC,KattanMW,GonenM,et al: Predicting nonsentinel node status after positive sentinel lymph biopsy for breast cancer: clinicians versus nomogram. Ann Surg Oncol 2005; 12:654-659
10. Addington J, Cadenhead KS, Cornblatt BA, et al: North American Prodrome Longitudinal Study (NAPLS 2): overviewand recruitment. Schizophr Res 2012; 142:77-82
11. McGlashan TH, Walsh BC, Woods SW: The Psychosis-Risk Syndrome: Handbook for Diagnosis and Follow-Up. New York, Oxford University Press, 2010
12. First M, Spitzer RL, Gibbon M, et al: Structured Clinical Interview for DSM-IV Axis I Disorders, Patient Edition. NewYork, Biometrics Research Department, New York State Psychiatric Institute, 1995
13. Miller TJ, McGlashan TH, Rosen JL, et al: Prospective diagnosis of the initial prodrome for schizophrenia based on the Structured Interview for Prodromal Syndromes: preliminary evidence of interrater reliability and predictive validity. Am J Psychiatry 2002; 159: 863-865
14. Kirkbride JB, Fearon P, Morgan C, et al: Heterogeneity in incidence rates of schizophrenia and other psychotic syndromes: findings from the 3-center AeSOP study. Arch Gen Psychiatry 2006; 63:250-258
15. Cannon TD, Chung Y, He G, et al: Progressive reduction in cortical thickness as psychosis develops: a multisite longitudinal neuroimaging study of youth at elevated clinical risk. Biol Psychiatry 2015; 77:147-157
16. McGlashan TH, Hoffman RE: Schizophrenia as a disorder of developmentally reduced synaptic connectivity. Arch Gen Psychiatry 2000; 57:637-648
17. Walker EF, Walder DJ, Reynolds F: Developmental changes in cortisol secretion in normal and at-risk youth. Dev Psychopathol 2001; 13:721-732
18. Riecher-Rössler A, Pflueger MO, Aston J, et al: Efficacy of using cognitive status in predicting psychosis: a 7-year follow-up. Biol Psychiatry 2009; 66:1023-1030
19. Seidman LJ, Giuliano AJ, Meyer EC, et al: Neuropsychology of the prodrome to psychosis in the NAPLS consortium: relationship to family history and conversion to psychosis. Arch Gen Psychiatry 2010; 67:578-588
20. Giuliano AJ, Li H, Mesholam-Gately RI, et al: Neurocognition in the psychosis risk syndrome: a quantitative and qualitative review. Curr Pharm Des 2012; 18:399-415
21. Keefe RS, Goldberg TE, Harvey PD, et al: The Brief Assessment of Cognition in Schizophrenia: reliability, sensitivity, and comparisonwith a standard neurocognitive battery. Schizophr Res 2004; 68:283-297
22. Brandt J, Benedict RHB: Hopkins Verbal Learning Test-Revised (HVLT-R). Odessa, Fla, Psychological Assessment Resources, 1998
23. Cornblatt BA, Carrion RE, Auther A, et al: Psychosis prevention: a modified clinical high risk perspective from the Recognition and Prevention (RAP) Program. Am J Psychiatry 2015; 172:986-994
24. Cornblatt BA, Auther AM, Niendam T, et al: Preliminary findings for two new measures of social and role functioning in the prodromal phase of schizophrenia. Schizophr Bull 2007; 33: 688-702
25. Holtzman CW, Shapiro DI, Trotman HD, et al: Stress and the prodromal phase of psychosis. Curr Pharm Des 2012; 18:527-533
26. Dohrenwend BS, Krasnoff L, Askenasy AR, et al: Exemplification of a methodfor scaling life events: the Peri Life Events Scale. J HealthSoc Behav 1978; 19:205-229
27. Janssen I, Krabbendam L, Bak M, et al: Childhood abuse as a risk factor for psychotic experiences. Acta Psychiatr Scand 2004; 109: 38-45
28. Sullivan PF: The genetics of schizophrenia. PLoS Med 2005; 2:e212
29. Uno H, Cai T, Pencina MJ, et al: On the C-statistics for evaluating overall adequacy of risk prediction procedures with censored survival data. Stat Med 2011; 30:1105-1117
30. Carrión RE, Cornblatt BA, Burton CZ, et al: Personalized prediction of psychosis: external validation of the NAPLS-2 psychosis risk calculator with the EDIPPP project. Am J Psychiatry 2016; 173:989-996
31. Ruhrmann S, Schultze-Lutter F, Salokangas RK, et al: Prediction of psychosis in adolescents and young adults at high risk: results from the prospective European Prediction of Psychosis Study. Arch Gen Psychiatry 2010; 67:241-251
32. Kattan MW: Doc, what are my chances? A conversation about prognostic uncertainty. Eur Urol 2011; 59:224
33. Koutsouleris N, Riecher-Rossler A, Meisenzahl EM, et al: Detecting the psychosis prodrome across high-risk populations using neuroanatomical biomarkers. Schizophr Bull 2015; 41:471-482
34. Perkins DO, Jeffries CD, Addington J, et al: Towards a psychosis risk blood diagnostic for persons experiencing high-risk symptoms: preliminary results from theNAPLSproject. Schizophr Bull 2015; 41: 419-428
35. Addington J, Cornblatt BA, Cadenhead KS, et al: At clinical high risk for psychosis: outcome for nonconverters. AmJ Psychiatry 2011; 168: 800-805
36. Schlosser DA, Jacobson S, Chen Q, et al: Recovery from an at-risk state: clinical and functionaloutcomesof putativelyprodromal youth who do not develop psychosis. Schizophr Bull 2012; 38:1225-1233
37. van der Gaag M, Smit F, Bechdolf A, et al: Preventing a first episode of psychosis: meta-analysis of randomized controlled prevention trials of 12month and longer-termfollow-ups. Schizophr Res 2013; 149:56-62
38. McGorry PD,YungAR,Phillips LJ, et al:Randomizedcontrolled trial of interventions designed to reduce the risk of progression to firstepisode psychosis in a clinical sample with subthreshold symptoms. Arch Gen Psychiatry 2002; 59:921-928
39. McGlashan TH, Zipursky RB, Perkins D, et al: Randomized, doubleblind trial of olanzapine versus placebo in patients prodromally symptomatic for psychosis. Am J Psychiatry 2006; 163:790-799
40. Amminger GP, Schäfer MR, Papageorgiou K, et al: Long-chain omega-3 fatty acids for indicated prevention of psychotic disorders: a randomized, placebo-controlled trial. Arch Gen Psychiatry 2010; 67:146-154
41. Miklowitz DJ, O'Brien MP, Schlosser DA, et al: Family-focused treatment for adolescents and young adults at high risk for psychosis: results of a randomized trial. J Am Acad Child Adolesc Psychiatry 2014; 53:848-858
42. Stafford MR, Jackson H, Mayo-Wilson E, et al: Early interventions to prevent psychosis: systematic review and meta-analysis. BMJ 2013; 346:f185